Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy

被引:0
|
作者
Stec, Maria [1 ]
Suleja, Agata [1 ]
Gondko, Daniel [1 ]
Kuczmik, Wiktoria [1 ]
Roman, Jakub [1 ]
Dziadosz, Dominika [2 ]
Szydlo, Krzysztof [2 ]
Mizia-Stec, Katarzyna [2 ]
机构
[1] Med Univ Silesia, Students Res Grp, Dept Cardiol 1, 47 Ziolowa St, PL-40635 Katowice, Poland
[2] Med Univ Silesia, Dept Cardiol 1, European Reference Network Heart Dis ERN GUARD HE, 47 Ziolowa St, PL-40635 Katowice, Poland
关键词
hypertrophic cardiomyopathy; atrial fibrillation; HCM-AF Risk Score; ATRIAL-FIBRILLATION; DIAGNOSIS; PROFILE;
D O I
10.3390/jcm12134484
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, p < 0.001; r = 0.346, p < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (p < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (p < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation The HCM-AF Score
    Carrick, Richard T.
    Maron, Martin S.
    Adler, Arnon
    Wessler, Benjamin
    Hoss, Sara
    Chan, Raymond H.
    Sridharan, Aadhavi
    Huang, Dou
    Cooper, Craig
    Drummond, Jennifer
    Rakowski, Harry
    Maron, Barry J.
    Rowin, Ethan J.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2021, 14 (06): : E009796
  • [2] External validation and extension of the HCM-AF score for the prediction of atrial fibrillation in hypertrophic cardiomyopathy patients.
    Calderon, G. German Cediel
    Ruiz-Cueto, M.
    Codina, P.
    Domingo, M.
    Borrellas, A.
    Santiago-Vacas, E.
    Ros-Pena, A.
    Garcia-Jimenez, B.
    Romero, G.
    Pulido, A.
    Crespo, E.
    Troya, M.
    Julian, M. T.
    Lupon, J.
    Bayes-Genis, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 373 - 374
  • [3] HCM-AF South Italy score for prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy: data from a derivation and validation italian cohorts
    Todde, G.
    Monda, E.
    Canciello, G.
    Lioncino, M.
    Lombardi, R.
    Rubino, M.
    Borrelli, F.
    Caiazza, M.
    Paoletta, D.
    De Simone, G.
    Pacileo, G.
    Esposito, G.
    Limongelli, G.
    Losi, M. A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1710 - 1710
  • [4] A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)
    O'Mahony, Constantinos
    Jichi, Fatima
    Pavlou, Menelaos
    Monserrat, Lorenzo
    Anastasakis, Aristides
    Rapezzi, Claudio
    Biagini, Elena
    Ramon Gimeno, Juan
    Limongelli, Giuseppe
    McKenna, William J.
    Omar, Rumana Z.
    Elliott, Perry M.
    EUROPEAN HEART JOURNAL, 2014, 35 (30) : 2010 - +
  • [5] Predictors of atrial fibrillation in hypertrophic cardiomyopathy (HCM Risk-AF)
    Guttmann, O. P.
    Elliott, P.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1191 - 1191
  • [6] CLINICAL PREDICTORS OF INFORMATIVE GENETIC TESTING IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY (HCM)
    Asswad, Amjad Ghazal
    Naraen, Akriti
    Fairbairn, Timothy
    Modi, Simon
    Shaw, Matthew
    Somauroo, John
    Stables, Rod
    Todd, Derick
    Mckay, Victoria
    Cooper, Rob
    HEART, 2019, 105 : A110 - A112
  • [7] Prediction of thromboembolic (TE) risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)
    Guttmann, O. P.
    Elliott, P.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1190 - 1190
  • [8] Hybrid versus catheter ablation for Hypertrophic CardioMyopathy with Atrial Fibrillation (HCM-AF): study protocol for a randomised controlled trial
    Tang, Yajie
    Li, Le
    Chen, Sipeng
    Xue, Yumei
    Guo, Huiming
    Song, Lei
    Tang, Min
    Yao, Yan
    Zheng, Zhe
    BMJ OPEN, 2024, 14 (10):
  • [9] Which Risk Score Best Assesses Clinical Objectives in Patients with Hypertrophic Cardiomyopathy?
    de Castro Roque, Eduardo Alberto
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2020, 115 (02) : 205 - 206
  • [10] Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)
    Guttmann, Oliver P.
    Pavlou, Menelaos
    O'Mahony, Constantinos
    Monserrat, Lorenzo
    Anastasakis, Aristides
    Rapezzi, Claudio
    Biagini, Elena
    Gimeno, Juan Ramon
    Limongelli, Giuseppe
    Garcia-Pavia, Pablo
    McKenna, William J.
    Omar, Rumana Z.
    Elliott, Perry M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (08) : 837 - 845